Efficacy and Safety of Trastuzumab Deruxtecan in Exploratory Cohorts of Patients with HER2-Low Gastric or Gastroesophageal Junction Adenocarcinoma
Exploratory cohort results from a phase II study in patients who had not received previously anti-HER2 treatment